Eli Lilly and Co. is investing $450 million and creating 100 new jobs at its Research Triangle Park, N.C., manufacturing facility.
The expansion will target additional parenteral filling, device assembly and packaging capacity to support increased demand for the company's diabetes treatment and testing products, according to a Jan. 24 Lilly news release.
Since 2020, Lilly has invested $4 billion into new manufacturing facilities in North Carolina.
"Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients rely on to address serious health challenges like diabetes," Edgardo Hernandez, Lilly executive vice president and president of Lilly manufacturing operations said. "We're on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future."